IN2014DN00101A - - Google Patents

Info

Publication number
IN2014DN00101A
IN2014DN00101A IN101DEN2014A IN2014DN00101A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A IN 101DEN2014 A IN101DEN2014 A IN 101DEN2014A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A
Authority
IN
India
Prior art keywords
dendrimer
macromolecules
pharmaceutically active
active agent
surface amino
Prior art date
Application number
Other languages
English (en)
Inventor
David Owen
Brian Devlin Kelly
Peter Karellas
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2014DN00101A publication Critical patent/IN2014DN00101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IN101DEN2014 2011-06-06 2012-06-06 IN2014DN00101A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493886P 2011-06-06 2011-06-06
PCT/AU2012/000647 WO2012167309A1 (en) 2011-06-06 2012-06-06 Macromolecules

Publications (1)

Publication Number Publication Date
IN2014DN00101A true IN2014DN00101A (no) 2015-05-15

Family

ID=47295262

Family Applications (1)

Application Number Title Priority Date Filing Date
IN101DEN2014 IN2014DN00101A (no) 2011-06-06 2012-06-06

Country Status (19)

Country Link
US (2) US9744246B2 (no)
EP (1) EP2729179B1 (no)
JP (1) JP6158177B2 (no)
KR (1) KR101941318B1 (no)
CN (2) CN110124051B (no)
AU (1) AU2012267200B2 (no)
BR (1) BR112013031556B1 (no)
CA (1) CA2837979C (no)
DK (1) DK2729179T3 (no)
ES (1) ES2834992T3 (no)
HK (1) HK1198356A1 (no)
HR (1) HRP20201998T1 (no)
HU (1) HUE052285T2 (no)
IN (1) IN2014DN00101A (no)
LT (1) LT2729179T (no)
PL (1) PL2729179T3 (no)
PT (1) PT2729179T (no)
SI (1) SI2729179T1 (no)
WO (1) WO2012167309A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
EP2996726A1 (fr) * 2013-05-16 2016-03-23 Université de Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
US11571480B2 (en) 2015-08-11 2023-02-07 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
WO2017068051A1 (en) * 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
WO2017135893A1 (en) * 2016-02-05 2017-08-10 Nipsea Technologies Pte Ltd Aqueous dendritic amine coatings
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
CA3095644A1 (en) * 2018-03-29 2019-10-03 Nof Corporation Degradable polyethylene glycol conjugate
CA3106568A1 (en) * 2018-07-19 2020-01-23 Starpharma Pty Ltd Therapeutic dendrimer
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物
WO2020102852A1 (en) * 2018-11-20 2020-05-28 Starpharma Pty Ltd Therapeutic dendrimer
CN113164615A (zh) * 2018-11-29 2021-07-23 星法马私人有限公司 用于治疗和成像的树状聚体
EP4021511A4 (en) * 2019-08-28 2023-10-04 Starpharma Pty Ltd TARGETED DENDRIMER CONJUGATES
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
CA3180877A1 (en) * 2020-06-03 2021-12-09 Starpharma Pty Ltd Therapeutic conjugates
JP2023538695A (ja) * 2020-08-25 2023-09-08 上海森輝医薬有限公司 薬剤を担持する高分子及びその調製方法
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate
IL300089A (en) * 2020-09-24 2023-03-01 Ocular Therapeutix Inc Sustained-release biological intracanalicular inserts comprising hydrogel and cyclosporine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101102787A (zh) * 2004-08-09 2008-01-09 艾丽奥斯生物制药有限公司 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
PL2052011T3 (pl) * 2006-08-11 2021-03-08 Starpharma Pty Limited Nakierowany środek terapeutyczny będący dendrymerem polilizynowym
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
JP5977229B2 (ja) * 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Also Published As

Publication number Publication date
CN103796684B (zh) 2019-06-25
HK1198356A1 (en) 2015-04-10
LT2729179T (lt) 2020-12-28
AU2012267200A1 (en) 2013-05-09
CA2837979C (en) 2021-03-30
JP2014520105A (ja) 2014-08-21
PL2729179T3 (pl) 2021-07-19
AU2012267200B2 (en) 2016-02-25
BR112013031556B1 (pt) 2022-03-29
ES2834992T3 (es) 2021-06-21
CA2837979A1 (en) 2012-12-13
EP2729179A4 (en) 2015-01-28
SI2729179T1 (sl) 2021-01-29
EP2729179A1 (en) 2014-05-14
US10265409B2 (en) 2019-04-23
KR101941318B1 (ko) 2019-01-22
CN103796684A (zh) 2014-05-14
US20140171375A1 (en) 2014-06-19
PT2729179T (pt) 2020-11-25
JP6158177B2 (ja) 2017-07-05
WO2012167309A1 (en) 2012-12-13
KR20140041678A (ko) 2014-04-04
EP2729179B1 (en) 2020-09-23
BR112013031556A2 (no) 2017-08-29
DK2729179T3 (da) 2020-12-21
CN110124051A (zh) 2019-08-16
CN110124051B (zh) 2022-10-21
HUE052285T2 (hu) 2021-04-28
HRP20201998T1 (hr) 2021-02-05
US20170354739A1 (en) 2017-12-14
US9744246B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
IN2014DN00101A (no)
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
WO2017044894A3 (en) Cartilage-homing peptides
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
MX348983B (es) Profarmacos que comprenden un conjugado de conector de exendina.
WO2011130615A3 (en) Preparation of lacosamide
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2012075086A3 (en) Fabric care composition
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2013019658A3 (en) Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
MY172292A (en) Vectors and sequences for the treatment of diseases
IN2012DN02736A (no)
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2013040242A3 (en) Dermal filler compositions for fine line treatment
IN2014DN08299A (no)
WO2012174158A3 (en) Administration of benzodiazepine
MX2014004196A (es) Citramida de rasagilina.
TN2014000185A1 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib